Statera BioPharma (FRA:7CB) Total Liabilities: €23.15 Mil (As of Sep. 2022)


FRA:7CB Statera BioPharma Inc FRA:7CB
20 GF Score
Price €2.61
View Full Analysis

What is Statera BioPharma Total Liabilities?

Statera BioPharma FRA:7CB 20 Total Liabilities is €23.15 Mil as of Sep. 2022. GuruFocus rates FRA:7CB with a GF Score™ of 20/100.

Statera BioPharma's Total Liabilities for the quarter that ended in Sep. 2022 was €23.15 Mil.

Statera BioPharma's quarterly Total Liabilities increased from Mar. 2022 (€14.48 Mil) to Jun. 2022 (€19.36 Mil) and increased from Jun. 2022 (€19.36 Mil) to Sep. 2022 (€23.15 Mil).

Statera BioPharma's annual Total Liabilities increased from Dec. 2019 (€3.79 Mil) to Dec. 2020 (€3.86 Mil) and increased from Dec. 2020 (€3.86 Mil) to Dec. 2021 (€20.07 Mil).

Statera BioPharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Total Liabilities Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Total Liabilities
3.79 3.86 20.07

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 20.27 20.07 14.48 19.36 23.15
FRA:7CB
20GF Score
Statera BioPharma Inc FRA:7CB
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Statera BioPharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Statera BioPharma's Total Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.952+(10.116+1.7763568394003E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=20.07

Total Liabilities=Total Assets (A: Dec. 2021 )-Total Equity (A: Dec. 2021 )
=18.735--1.334
=20.07

Statera BioPharma's Total Liabilities for the quarter that ended in Sep. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.453+(0.693+1.4432899320127E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=23.15

Total Liabilities=Total Assets (Q: Sep. 2022 )-Total Equity (Q: Sep. 2022 )
=12.876--10.27
=23.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €23.15 Mil mean?
Statera BioPharma (FRA:7CB) has a Total Liabilities of €23.15 Mil as of Sep. 2022. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Statera BioPharma and its competitors.
Is Statera BioPharma's Total Liabilities too high?
Statera BioPharma's current Total Liabilities is €23.15 Mil. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's Total Liabilities compare to NRBO and PALI?
Statera BioPharma's Total Liabilities of €23.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Statera BioPharma and its competitors. Statera BioPharma's current Total Liabilities is €23.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (FRA:7CB) has a current Total Liabilities of €23.15 Mil. The current Total Liabilities is €23.15 Mil. Statera BioPharma's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Statera BioPharma (FRA:7CB), the current Total Liabilities is €23.15 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
20GF Score

Get the complete analysis for FRA:7CB

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.61
Price